Grail
In Brief This Week: Meridian Bioscience, BioMérieux, Applied DNA Sciences, More
News items for the week of Dec. 12, 2022.
European Commission Outlines Intended Restorative Measures for Blocked Illumina-Grail Deal
In a Statement of Objections, the agency laid out the intended divestment and transitional measures for Illumina to unwind and dissolve the Grail acquisition.
Illumina Lowers FY 2022 Guidance as Q3 Revenues Rise 1 Percent
Illumina is taking a $3.91 billion write-off related to Grail triggered by regulatory decisions in Europe, resulting in a net loss for the quarter.
In Brief This Week: Thermo Fisher Scientific, Enzo Biochem, Codex DNA, More
News items for the week of Oct. 10, 2022.
ESMO Data Sharpens View of How Grail, Exact Sciences Multi-Cancer Early Detection Tests Perform
Premium
Grail released updated data on Galleri from the PATHFINDER study, while Exact reported retrospective analysis on the performance of its test.
Sep 6, 2022
EU to Disallow Illumina's Grail Purchase
Aug 12, 2022
May 5, 2022
Illumina Q1 Revenues Grow 12 Percent
Nov 4, 2021